Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 21,376 shares at $20.02 ($428K) on 2025-08-18, disclosed to the SEC on 2025-08-20.
Scheduled sale ($428k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.02 | 10,393 | $208K | 48.6% |
| 2 | $20.02 | 10,393 | $208K | 48.6% |
| 3 | $20.00 | 590 | $12K | 2.8% |
| Total | $20.02 avg | 21,376 | $428K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |